Search results

Evidence-based recommendations on avapritinib (Ayvakyt) for treating advanced systemic mastocytosis in adults.

Result type

Technology appraisal guidance

Published

6 November 2024

NICE is unable to make a recommendation on duvelisib (Copiktra) for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments because Secura Bio withdrew its evidence submission.

Result type

Technology appraisal guidance

Published

27 July 2022

Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

30 September 2020

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.

Result type

Technology appraisal guidance

Published

1 February 2023

Evidence-based recommendations on somatrogon (Ngenla) for treating growth disturbance in children and young people aged 3 years and over.

Result type

Technology appraisal guidance

Published

1 February 2023

Evidence-based recommendations on nintedanib (Ofev) for treating idiopathic pulmonary fibrosis in adults when forced vital capacity is above 80% predicted.

Result type

Technology appraisal guidance

Published

1 February 2023

Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

Result type

Technology appraisal guidance

Published

25 August 2010

Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults.

Result type

Technology appraisal guidance

Published

11 January 2023

Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

11 January 2023

Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.

Result type

Technology appraisal guidance

Published

18 January 2023

Evidence-based recommendations on upadacitinib (Rinvoq) for treating active non-radiographic axial spondyloarthritis in adults.

Result type

Technology appraisal guidance

Published

1 February 2023

Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

8 February 2023

Evidence-based recommendations on vutrisiran (Amvuttra) for treating hereditary transthyretin-related amyloidosis in adults.

Result type

Technology appraisal guidance

Published

15 February 2023

Evidence-based recommendations on Ixazomib (Ninlaro) with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.

Result type

Technology appraisal guidance

Published

22 February 2023

Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.

Result type

Technology appraisal guidance

Published

1 March 2023